4.26
+0(+0.00%)
Currency In USD
| Previous Close | 4.26 |
| Open | 4.24 |
| Day High | 4.26 |
| Day Low | 4.24 |
| 52-Week High | 4.5 |
| 52-Week Low | 1.8 |
| Volume | 8.63M |
| Average Volume | 3.08M |
| Market Cap | 367.72M |
| PE | -3.33 |
| EPS | -1.28 |
| Moving Average 50 Days | 4.09 |
| Moving Average 200 Days | 3.33 |
| Change | 0 |
If you invested $1000 in Checkpoint Therapeutics, Inc. (CKPT) since IPO date, it would be worth $85.2 as of August 18, 2025 at a share price of $4.26. Whereas If you bought $1000 worth of Checkpoint Therapeutics, Inc. (CKPT) shares 5 years ago, it would be worth $175.31 as of August 18, 2025 at a share price of $4.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
GlobeNewswire Inc.
Dec 13, 2024 11:15 PM GMT
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
GlobeNewswire Inc.
Sep 16, 2024 11:30 AM GMT
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and